LICENSE: This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.


8100437
6047
Neurobiol Aging
Neurobiol. Aging
Neurobiology of aging
0197-4580
1558-1497

27666590
5154872
10.1016/j.neurobiolaging.2016.08.023
NIHMS826260
Article
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies
Kun-Rodrigues Celia a
Ross Owen A. b
Orme Tatiana a
Shepherd Claire cd
Parkkinen Laura e
Darwent Lee a
Hernandez Dena f
Ansorge Olaf e
Clark Lorraine N. gh
Honig Lawrence S. gh
Marder Karen gh
Lemstra Afina i
Scheltens Philippe i
van der Flier Wiesje i
Louwersheimer Eva i
Holstege Henne i
Rogaeva Ekaterina j
George-Hyslop Peter St. j
Londos Elisabet k
Zetterberg Henrik lm
Barber Imelda n
Braae Anne n
Brown Kristelle n
Morgan Kevin n
Maetzler Walter op
Berg Daniela op
Troakes Claire q
Al-Sarraj Safa q
Lashley Tammaryn r
Holton Janice r
Compta Yaroslau s
Van Deerlin Vivianna t
Trojanowski John Q. t
Serrano Geidy E. u
Beach Thomas G. u
Clarimon Jordi v
Lleó Alberto v
Morenas-Rodríguez Estrella v
Lesage Suzanne wx
Galasko Douglas yz
Masliah Eliezer yz
Santana Isabel aa
Diez Monica bbcc
Pastor Pau bbcc
Tienari Pentti J. dd
Myllykangas Liisa ee
Oinas Minna ff
Revesz Tamas r
Lees Andrew r
Boeve Brad F. gg
Petersen Ronald C. gg
Ferman Tanis J. hhii
Escott-Price Valentina jj
Graff-Radford Neill kk
Cairns Nigel J. ll
Morris John C. ll
Stone David J. mm
Pickering-Brown Stuart nn
Mann David nn
Dickson Dennis W. b
Halliday Glenda M. cd
Singleton Andrew f
Guerreiro Rita oopp
Bras Jose oopp*
a Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
b Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
c Neuroscience Research Australia, Sydney, Australia
d School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia
e Nuffield Department of Clinical Neurosciences, Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, UK
f Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD, USA
g Taub Institute for Alzheimer Disease and the Aging Brain, Columbia University, New York, NY, USA
h Department of Pathology and Cell Biology, Columbia University, New York, NY, USA
i Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
j Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
k Clinical Memory Research Unit, Institution of Clinical Sciences Malmö, Lund University, Lund, Sweden
l Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
m Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
n Translation Cell Sciences–Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK
o Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, Center of Neurology, University of Tuebingen, Tuebingen, Germany
p Department of Neurology, Christian-Albrechts University of Kiel, Kiel, Germany
q Department of Basic and Clinical Neuroscience and Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
r Queen Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
s Movement Disorders Unit, Neurology Service, Clinical Neuroscience Institute (ICN), Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain
t Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
u Banner Sun Health Research Institute, Sun City, AZ, USA
v Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universidad Autònoma de Barcelona, Barcelona, Catalonia, Spain
w Sorbonne Université, Université Pierre et Marie Curie-Paris 06, Inserm, Centre National de la Reserche Scientifique, Institute du Cerveau et de la Moelle épinière, Paris, France
x Assistance Publique Hôpitaux de Paris, Hôpital de la Salpêtrière, Département de Génétique et Cytogénétique, Paris, France
y Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
z Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA
aa Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
bb Memory Unit, Department of Neurology, University Hospital Mútua de Terrassa, and Foundation Mútua de Terrassa, Barcelona, Spain
cc Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
dd Molecular Neurology, Research Programs Unit, University of Helsinki, Department of Neurology, Helsinki University Hospital, Helsinki, Finland
ee Department of Pathology, University of Helsinki, Helsinki, Finland and HUSLAB
ff Department of Neuropathology and Neurosurgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
gg Neurology Department, Mayo Clinic, Rochester, MN, USA
hh Department of Psychiatry, Mayo Clinic, Jacksonville, FL, USA
ii Department of Psychology, Mayo Clinic, Jacksonville, FL, USA
jj MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK
kk Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
ll Knight Alzheimer’s Disease Research Center, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
mm Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA
nn Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
oo Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
pp Department of Medical Sciences and Institute of Biomedicine–iBiMED, University of Aveiro, Aveiro, Portugal
* Corresponding author at: Department of Molecular Neuroscience, 1 Wakefield Street (1st Floor), London WC1N 1PJ, England. Tel.: +44 (0) 207 679 4256; fax: +44 (0)20 7833 1016
31 10 2016
02 9 2016
1 2017
01 1 2018
49 214.e13214.e15
This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
C9orf72 repeat expansions are a common cause of amyotrophic lateral sclerosis and frontotemporal dementia. To date, no large-scale study of dementia with Lewy bodies (DLB) has been undertaken to assess the role of C9orf72 repeat expansions in the disease. Here, we investigated the prevalence of C9orf72 repeat expansions in a large cohort of DLB cases and identified no pathogenic repeat expansions in neuropathologically or clinically defined cases, showing that C9orf72 repeat expansions are not causally associated with DLB.

C9orf72
Dementia with Lewy bodies (DLB)
Genetic screen

1. Introduction

Hexanucleotide repeat expansions (HREs) in a noncoding region of C9orf72 are recognized as the most common genetic cause of familial and sporadic amyotrophic lateral sclerosis, frontotemporal dementia (FTD), amyotrophic lateral sclerosis-FTD, and Huntington disease phenocopies (Beck et al., 2013; Boeve et al., 2012; Hensman Moss et al., 2014; Majounie et al., 2012c; Simon-Sanchez et al., 2012; van der Zee et al., 2013).

A normal repeat expansion shows 1 to 23 GGGGCC repeats located between exons 1a and 1b of C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). HREs identified in several neurodegenerative syndromes were found to range from 500 to 4400 repeats, but on a repeat-primed polymerase chain reaction (PCR), more than 32 repeats are often considered a pathogenic genotype (Beck et al., 2013).

C9orf72 HREs have been identified in nonmotor neurodegenerative phenotypes including Alzheimer’s disease (AD) at frequencies of ~1% (Beck et al., 2013; Harms et al., 2013; Kohli et al., 2013; Majounie et al., 2012b), although conflicting reports exist in the literature (Rollinson et al., 2012; Xi et al., 2012).

Dementia with Lewy bodies (DLB) accounts for 15%–25% of all dementia cases (Heidebrink, 2002). Its core features encompass cognitive impairment, fluctuating attention, parkinsonism, and recurrent visual hallucinations (Weisman and McKeith, 2007). Neuropathological diagnosis of DLB is achieved when the presence of Lewy bodies is confirmed in the cortex and the brainstem (McKeith et al., 2005). Little is known about the genetics of DLB, although molecular studies seem to point toward genetic overlaps with other neurodegenerative diseases, mainly with AD and Parkinson’s disease (PD) (Bras et al., 2014; Guerreiro et al., 2016; Keogh et al., 2016; Meeus et al., 2012).

So far, the C9orf72 repeat expansion has only been genotyped in small cohorts of ~100 DLB cases or less (Geiger et al., 2016; Lesage et al., 2013; Robinson et al., 2014; Snowden et al., 2012; Yeh et al., 2013). We have recently shown in a large cohort that C9orf72 repeat expansions are not a common cause of DLB in pathologically diagnosed cases (Guerreiro et al., 2015). Here, we expand on these findings using a cohort of 1524 DLB cases.

2. Material and methods

Samples consisted of an international cohort of 1398 neuropathologically diagnosed DLB cases and 126 clinically diagnosed DLB cases (Supplementary Table 1). DNA was extracted from brain tissue for the neuropathologically diagnosed samples and from blood for the clinical diagnosed samples using standard procedures. We performed repeat-primed PCR according to Renton et al. (2011). Genotypes were assessed using Peak Scanner v2.0 (Applied Biosystems) with repeat expansions displaying a characteristic saw tooth pattern with a 6 base pair periodicity on analysis.

3. Results

Repeat mean number was 5.17 (±4.30 standard deviation) ranging from 1 to 58. All except 5 samples presented less than 23 repeats in the repeat-primed PCR (Supplementary Fig. 1). Two neuropathologically diagnosed DLB samples showed 32 repeats and 1 showed 33 repeats; and 2 clinically diagnosed samples exhibited 33 and 58 repeats. These last 2 samples had been previously analyzed as part of the cohort published by Snowden et al. (2012).

4. Discussion

This is the first study genotyping the C9orf72 HREs in a large cohort of mainly neuropathologically diagnosed DLB samples. Within the neuropathologically defined DLB cases, we did not find any HREs above the typical threshold for pathogenicity (~32 repeats). This is concordant with previous studies that found no repeat expansions in 34 clinically diagnosed cases of a Taiwanese cohort or in 111 pathological DLB cases (Geiger et al., 2016; Yeh et al., 2013). Snowden et al. (2012) found 2 cases with HREs greater than 30 repeats in a study that was comprised of 102 “probable DLB” blood samples. When the same group restricted their analysis to include only pathologically diagnosed samples, no pathogenic repeat expansions were identified (Robinson et al., 2014).

DLB is considered to be part of a spectrum between AD and PD (Weisman and McKeith, 2007) where large C9orf72 HREs are not frequent. In AD, it was suggested that pathogenic repeat expansions may only be associated with late onset AD (Kohli et al., 2013) or that amnesic FTD (which is easily misdiagnosed as AD) could be responsible for the low frequencies observed for AD (Majounie et al., 2012b). In PD, there is no evidence for a role of C9orf72 pathogenic repeat expansions (Majounie et al., 2012a; Xi et al., 2012).

Clinical symptoms in DLB can vary substantially from patient to patient and some can even overlap with less typical forms of FTD (Claassen et al., 2008), which could account for the pathogenic repeat expansions found in misdiagnosed DLB clinical cases. Furthermore, recent data suggest that the threshold for pathogenicity of HREs should be higher than the initially proposed 30 repeats (Xi et al., 2015).

In our cohort of neuropathologically diagnosed DLB samples, we found 3 cases with likely benign 32 and 33 repeats. Excluding the clinically diagnosed cases, we found no evidence of pathogenic repeat expansions. Even including the clinically diagnosed cohort, no extended repeat expansions were identified; with the longest allele exhibiting 58 repeats.

Our study shows that C9orf72 pathogenic repeat expansions are not a common cause of DLB.

Supplementary Material

C9orf72_DLB

This work was supported in part by the National Institutes of Neurological Disease and Stroke. Jose Bras and Rita Guerreiro are supported by fellowships from the Alzheimer’s Society. Tatiana Orme is supported by a scholarship from the Lewy Body Society. For the neuropathologically confirmed samples from Australia, tissues were received from the Sydney Brain Bank, which is supported by Neuroscience Research Australia and the University of New South Wales. This study was also partially funded by the Wellcome Trust, Medical Research Council, Canadian Institutes of Health Research, and Ontario Research Fund. The Nottingham Genetics Group is supported by ARUK and The Big Lottery Fund. The effort from Columbia University was supported by the Taub Institute, the Panasci Fund, the Parkinson’s Disease Foundation, and NIH grants NS060113 (Dr Clark), P50AG008702 (P.I. Scott Small), P50NS038370 (P.I.R. Burke), and UL1TR000040 (P.I.H. Ginsberg). Dr Ross is supported by the Michael J. Fox Foundation for Parkinson’s Research, NINDS R01# NS078086. The Mayo Clinic Jacksonville is a Morris K. Udall Parkinson’s Disease Research Center of Excellence (NINDS P50 #NS072187) and is supported by The Little Family Foundation and by the Mangurian Foundation Program for Lewy Body Dementia research and the Alzheimer Disease Research Center (P50 AG016547). The work from the Mayo Clinic Rochester is supported by the National Institute on Aging (P50 AG016574 and U01 AG006786). This work has received support from The Queen Square Brain Bank at the UCL Institute of Neurology; where Dr Lashley is funded by an ARUK senior fellowship. Some of the tissue samples studied were provided by the MRC London Neurodegenerative Diseases Brain Bank and the Brains for Dementia Research project (funded by Alzheimer’s Society and ARUK). This research was supported in part by both the NIHR UCLH Biomedical Research Centre and the Queen Square Dementia Biomedical Research Unit. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project AG000951-12. The University of Pennsylvania case collection is funded by the Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K. Udall Parkinson’s Disease Research Center (NS053488). The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about. Tissue samples from UCSD are supported by NIH grant AG05131. The authors thank the brain bank GIE NeuroCEB, the French program “Investissements d’avenir” (ANR-10-IAIHU-06). Dr Tienari and Dr Myllykangas are supported by the Helsinki University Central Hospital, the Folkhälsan Research Foundation and the Finnish Academy. This work was in part supported by the Canadian Consortium on Neurodegeneration in Aging (ER).

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.neurobiolaging.2016.08.023.

Disclosure statement

Ronald C. Petersen reports consultancies with Roche, Inc, Merck, Inc, Genentech, Inc, Biogen, Inc, and Eli Lilly. Brad F. Boeve reports GE Healthcare, FORUM Pharmaceuticals, and C2N Diagnostics as research support and advisory board member of the Tau Consortium. The remaining authors report no competing interests.


Beck J Poulter M Hensman D Rohrer JD Mahoney CJ Adamson G Campbell T Uphill J Borg A Fratta P Orrell RW Malaspina A Rowe J Brown J Hodges J Sidle K Polke JM Houlden H Schott JM Fox NC Rossor MN Tabrizi SJ Isaacs AM Hardy J Warren JD Collinge J Mead S 2013 Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population Am J Hum Genet 92 3 345 353 10.1016/j.ajhg.2013.01.011 23434116
Boeve BF Boylan KB Graff-Radford NR DeJesus-Hernandez M Knopman DS Pedraza O Vemuri P Jones D Lowe V Murray ME Dickson DW Josephs KA Rush BK Machulda MM Fields JA Ferman TJ Baker M Rutherford NJ Adamson J Wszolek ZK Adeli A Savica R Boot B Kuntz KM Gavrilova R Reeves A Whitwell J Kantarci K Jack CR Jr Parisi JE Lucas JA Petersen RC Rademakers R 2012 Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72 Brain 135 Pt 3 765 783 10.1093/brain/aws004 22366793
Bras J Guerreiro R Darwent L Parkkinen L Ansorge O Escott-Price V Hernandez DG Nalls MA Clark LN Honig LS Marder K Van Der Flier WM Lemstra A Scheltens P Rogaeva E St George-Hyslop P Londos E Zetterberg H Ortega-Cubero S Pastor P Ferman TJ Graff-Radford NR Ross OA Barber I Braae A Brown K Morgan K Maetzler W Berg D Troakes C Al-Sarraj S Lashley T Compta Y Revesz T Lees A Cairns N Halliday GM Mann D Pickering-Brown S Dickson DW Singleton A Hardy J 2014 Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies Hum Mol Genet 23 23 6139 6146 10.1093/hmg/ddu334 24973356
Claassen DO Parisi JE Giannini C Boeve BF Dickson DW Josephs KA 2008 Frontotemporal dementia mimicking dementia with Lewy bodies Cogn Behav Neurol 21 3 157 163 10.1097/WNN.0b013e3181864a09 18797258
DeJesus-Hernandez M Mackenzie IR Boeve BF Boxer AL Baker M Rutherford NJ Nicholson AM Finch NA Flynn H Adamson J Kouri N Wojtas A Sengdy P Hsiung GY Karydas A Seeley WW Josephs KA Coppola G Geschwind DH Wszolek ZK Feldman H Knopman DS Petersen RC Miller BL Dickson DW Boylan KB Graff-Radford NR Rademakers R 2011 Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS Neuron 72 2 245 256 10.1016/j.neuron.2011.09.011 21944778
Geiger JT Arthur KC Dawson TM Rosenthal LS Pantelyat A Albert M Hillis AE Crain B Pletnikova O Troncoso JC Scholz SW 2016 C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies Neurodegener Dis 16 5–6 370 372 10.1159/000445872 27241037
Guerreiro R Escott-Price V Darwent L Parkkinen L Ansorge O Hernandez DG Nalls MA Clark L Honig L Marder K van der Flier W Holstege H Louwersheimer E Lemstra A Scheltens P Rogaeva E St George-Hyslop P Londos E Zetterberg H Ortega-Cubero S Pastor P Ferman TJ Graff-Radford NR Ross OA Barber I Braae A Brown K Morgan K Maetzler W Berg D Troakes C Al-Sarraj S Lashley T Compta Y Revesz T Lees A Cairns NJ Halliday GM Mann D Pickering-Brown S Powell J Lunnon K Lupton MK International Parkinson’s Disease Genomics, C. Dickson D Hardy J Singleton A Bras J 2016 Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson’s and Alzheimer’s diseases Neurobiol Aging 38 214 e217 214 e210 10.1016/j.neurobiolaging.2015.10.028
Guerreiro R Kun-Rodrigues C Darwent L Orme T Parkkinen L Ansorge O Clark L Honig L Marder K van der Flier W Lemstra A Scheltens P Rogaeva E St George-Hyslop P Londos E Zetterberg H Ortega-Cubero S Pastor P Barber I Braae A Brown K Morgan K Maetzler W Berg D Troakes C Al-Sarraj S Lashley T Compta Y Van Deerlin VM Trojanowski JQ Clarimon J Lesage S Galasko D Masliah E Tienari PJ Revesz T Lees A Ferman TJ Graff-Radford NR Ross OA Dickson D Escott-Price V Cairns N Halliday G Mann D Pickering-Brown S Singleton A Hardy J Bras J 2015 C9ORF72 in a Large International Cohort of Neuropathologically diagnosed Dementia with Lewy Bodies Cases Am J Neurodegener Dis 4 Suppl 1 1 178 26389015
Harms M Benitez BA Cairns N Cooper B Cooper P Mayo K Carrell D Faber K Williamson J Bird T Diaz-Arrastia R Foroud TM Boeve BF Graff-Radford NR Mayeux R Chakraverty S Goate AM Cruchaga C Consortium N.-L.N.F.S. 2013 C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease JAMA Neurol 70 6 736 741 10.1001/2013.jamaneurol.537 23588422
Heidebrink JL 2002 Is dementia with Lewy bodies the second most common cause of dementia? J Geriatr Psychiatry Neurol 15 4 182 187 12489913
Hensman Moss DJ Poulter M Beck J Hehir J Polke JM Campbell T Adamson G Mudanohwo E McColgan P Haworth A Wild EJ Sweeney MG Houlden H Mead S Tabrizi SJ 2014 C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies Neurology 82 4 292 299 10.1212/WNL.0000000000000061 24363131
Keogh MJ Kurzawa-Akanbi M Griffin H Douroudis K Ayers KL Hussein RI Hudson G Pyle A Cordell HJ Attems J McKeith IG O’Brien JT Burn DJ Morris CM Thomas AJ Chinnery PF 2016 Exome sequencing in dementia with Lewy bodies Transl Psychiatry 6 e728 10.1038/tp.2015.220 26836416
Kohli MA John-Williams K Rajbhandary R Naj A Whitehead P Hamilton K Carney RM Wright C Crocco E Gwirtzman HE Lang R Beecham G Martin ER Gilbert J Benatar M Small GW Mash D Byrd G Haines JL Pericak-Vance MA Zuchner S 2013 Repeat expansions in the C9ORF72 gene contribute to Alzheimer’s disease in Caucasians Neurobiol Aging 34 5 1519 e1515 1512 10.1016/j.neurobiolaging.2012.10.003
Lesage S Le Ber I Condroyer C Broussolle E Gabelle A Thobois S Pasquier F Mondon K Dion PA Rochefort D Rouleau GA Durr A Brice A French Parkinson’s Disease Genetics Study, G. 2013 C9orf72 repeat expansions are a rare genetic cause of parkinsonism Brain 136 Pt 2 385 391 10.1093/brain/aws357 23413259
Majounie E Abramzon Y Renton AE Keller MF Traynor BJ Singleton AB 2012a Large C9orf72 repeat expansions are not a common cause of Parkinson’s disease Neurobiol Aging 33 10 2527 e2521 2522 10.1016/j.neurobiolaging.2012.05.007
Majounie E Abramzon Y Renton AE Perry R Bassett SS Pletnikova O Troncoso JC Hardy J Singleton AB Traynor BJ 2012b Repeat expansion in C9ORF72 in Alzheimer’s disease N Engl J Med 366 3 283 284 10.1056/NEJMc1113592 22216764
Majounie E Renton AE Mok K Dopper EG Waite A Rollinson S Chio A Restagno G Nicolaou N Simon-Sanchez J van Swieten JC Abramzon Y Johnson JO Sendtner M Pamphlett R Orrell RW Mead S Sidle KC Houlden H Rohrer JD Morrison KE Pall H Talbot K Ansorge O Chromosome, A.L.S.F.T.D.C., French research network on, F.F.A., Consortium, I. Hernandez DG Arepalli S Sabatelli M Mora G Corbo M Giannini F Calvo A Englund E Borghero G Floris GL Remes AM Laaksovirta H McCluskey L Trojanowski JQ Van Deerlin VM Schellenberg GD Nalls MA Drory VE Lu CS Yeh TH Ishiura H Takahashi Y Tsuji S Le Ber I Brice A Drepper C Williams N Kirby J Shaw P Hardy J Tienari PJ Heutink P Morris HR Pickering-Brown S Traynor BJ 2012c Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study Lancet Neurol 11 4 323 330 10.1016/S1474-4422(12)70043-1 22406228
McKeith IG Dickson DW Lowe J Emre M O’Brien JT Feldman H Cummings J Duda JE Lippa C Perry EK Aarsland D Arai H Ballard CG Boeve B Burn DJ Costa D Del Ser T Dubois B Galasko D Gauthier S Goetz CG Gomez-Tortosa E Halliday G Hansen LA Hardy J Iwatsubo T Kalaria RN Kaufer D Kenny RA Korczyn A Kosaka K Lee VM Lees A Litvan I Londos E Lopez OL Minoshima S Mizuno Y Molina JA Mukaetova-Ladinska EB Pasquier F Perry RH Schulz JB Trojanowski JQ Yamada M Consortium on, D.L.B. 2005 Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 12 1863 1872 10.1212/01.wnl.0000187889.17253.b1 16237129
Meeus B Verstraeten A Crosiers D Engelborghs S Van den Broeck M Mattheijssens M Peeters K Corsmit E Elinck E Pickut B Vandenberghe R Cras P De Deyn PP Van Broeckhoven C Theuns J 2012 DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol Aging 33 3 629 e625 629 e618 10.1016/j.neurobiolaging.2011.10.014
Renton AE Majounie E Waite A Simon-Sanchez J Rollinson S Gibbs JR Schymick JC Laaksovirta H van Swieten JC Myllykangas L Kalimo H Paetau A Abramzon Y Remes AM Kaganovich A Scholz SW Duckworth J Ding J Harmer DW Hernandez DG Johnson JO Mok K Ryten M Trabzuni D Guerreiro RJ Orrell RW Neal J Murray A Pearson J Jansen IE Sondervan D Seelaar H Blake D Young K Halliwell N Callister JB Toulson G Richardson A Gerhard A Snowden J Mann D Neary D Nalls MA Peuralinna T Jansson L Isoviita VM Kaivorinne AL Holtta-Vuori M Ikonen E Sulkava R Benatar M Wuu J Chio A Restagno G Borghero G Sabatelli M Consortium I Heckerman D Rogaeva E Zinman L Rothstein JD Sendtner M Drepper C Eichler EE Alkan C Abdullaev Z Pack SD Dutra A Pak E Hardy J Singleton A Williams NM Heutink P Pickering-Brown S Morris HR Tienari PJ Traynor BJ 2011 A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD Neuron 72 2 257 268 10.1016/j.neuron.2011.09.010 21944779
Robinson A Davidson Y Snowden JS Mann DM 2014 C9ORF72 in dementia with Lewy bodies J Neurol Neurosurg Psychiatry 85 12 1435 1436 10.1136/jnnp-2014-307622 24648039
Rollinson S Halliwell N Young K Callister JB Toulson G Gibbons L Davidson YS Robinson AC Gerhard A Richardson A Neary D Snowden J Mann DM Pickering-Brown SM 2012 Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer’s disease Neurobiol Aging 33 8 1846 e1845 1846 10.1016/j.neurobiolaging.2012.01.109
Simon-Sanchez J Dopper EG Cohn-Hokke PE Hukema RK Nicolaou N Seelaar H de Graaf JR de Koning I van Schoor NM Deeg DJ Smits M Raaphorst J van den Berg LH Schelhaas HJ De Die-Smulders CE Majoor-Krakauer D Rozemuller AJ Willemsen R Pijnenburg YA Heutink P van Swieten JC 2012 The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions Brain 135 Pt 3 723 735 10.1093/brain/awr353 22300876
Snowden JS Rollinson S Lafon C Harris J Thompson J Richardson AM Jones M Gerhard A Neary D Mann DM Pickering-Brown S 2012 Psychosis, C9ORF72 and dementia with Lewy bodies J Neurol Neurosurg Psychiatry 83 10 1031 1032 10.1136/jnnp-2012-303032 22832738
van der Zee J Gijselinck I Dillen L Van Langenhove T Theuns J Engelborghs S Philtjens S Vandenbulcke M Sleegers K Sieben A Baumer V Maes G Corsmit E Borroni B Padovani A Archetti S Perneczky R Diehl-Schmid J de Mendonca A Miltenberger-Miltenyi G Pereira S Pimentel J Nacmias B Bagnoli S Sorbi S Graff C Chiang HH Westerlund M Sanchez-Valle R Llado A Gelpi E Santana I Almeida MR Santiago B Frisoni G Zanetti O Bonvicini C Synofzik M Maetzler W Vom Hagen JM Schols L Heneka MT Jessen F Matej R Parobkova E Kovacs GG Strobel T Sarafov S Tournev I Jordanova A Danek A Arzberger T Fabrizi GM Testi S Salmon E Santens P Martin JJ Cras P Vandenberghe R De Deyn PP Cruts M Van Broeckhoven C van der Zee J Gijselinck I Dillen L Van Langenhove T Theuns J Philtjens S Sleegers K Baumer V Maes G Corsmit E Cruts M Van Broeckhoven C van der Zee J Gijselinck I Dillen L Van Langenhove T Philtjens S Theuns J Sleegers K Baumer V Maes G Cruts M Van Broeckhoven C Engelborghs S De Deyn PP Cras P Engelborghs S De Deyn PP Vandenbulcke M Vandenbulcke M Borroni B Padovani A Archetti S Perneczky R Diehl-Schmid J Synofzik M Maetzler W Muller Vom Hagen J Schols L Synofzik M Maetzler W Muller Vom Hagen J Schols L Heneka MT Jessen F Ramirez A Kurzwelly D Sachtleben C Mairer W de Mendonca A Miltenberger-Miltenyi G Pereira S Firmo C Pimentel J Sanchez-Valle R Llado A Antonell A Molinuevo J Gelpi E Graff C Chiang HH Westerlund M Graff C Kinhult Stahlbom A Thonberg H Nennesmo I Borjesson-Hanson A Nacmias B Bagnoli S Sorbi S Bessi V Piaceri I Santana I Santiago B Santana I Helena Ribeiro M Rosario Almeida M Oliveira C Massano J Garret C Pires P Frisoni G Zanetti O Bonvicini C Sarafov S Tournev I Jordanova A Tournev I Kovacs GG Strobel T Heneka MT Jessen F Ramirez A Kurzwelly D Sachtleben C Mairer W Jessen F Matej R Parobkova E Danel A Arzberger T Maria Fabrizi G Testi S Ferrari S Cavallaro T Salmon E Santens P Cras P European Early-Onset Dementia, C. 2013 A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats Hum Mutat 34 2 363 373 10.1002/humu.22244 23111906
Weisman D McKeith I 2007 Dementia with Lewy bodies Semin Neurol 27 1 42 47 10.1055/s-2006-956754 17226740
Xi Z Zhang M Bruni AC Maletta RG Colao R Fratta P Polke JM Sweeney MG Mudanohwo E Nacmias B Sorbi S Tartaglia MC Rainero I Rubino E Pinessi L Galimberti D Surace EI McGoldrick P McKeever P Moreno D Sato C Liang Y Keith J Zinman L Robertson J Rogaeva E 2015 The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients Acta Neuropathol 129 5 715 727 10.1007/s00401-015-1401-8 25716178
Xi Z Zinman L Grinberg Y Moreno D Sato C Bilbao JM Ghani M Hernandez I Ruiz A Boada M Moron FJ Lang AE Marras C Bruni A Colao R Maletta RG Puccio G Rainero I Pinessi L Galimberti D Morrison KE Moorby C Stockton JD Masellis M Black SE Hazrati LN Liang Y van Haersma de With J Fornazzari L Villagra R Rojas-Garcia R Clarimon J Mayeux R Robertson J St George-Hyslop P Rogaeva E 2012 Investigation of c9orf72 in 4 neurodegenerative disorders Arch Neurol 69 12 1583 1590 10.1001/archneurol.2012.2016 22964832
Yeh TH Lai SC Weng YH Kuo HC Wu-Chou YH Huang CL Chen RS Chang HC Traynor B Lu CS 2013 Screening for C9orf72 repeat expansions in parkinsonian syndromes Neurobiol Aging 34 4 1311 e1313 1314 10.1016/j.neurobiolaging.2012.09.002
